EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong – A cost-effectiveness analysis

INTRODUCTION: Tyrosine kinase inhibitors (TKIs) therapy targets at epidermal growth factor receptor (EGFR) gene mutations in non-small-cell lung cancer (NSCLC). We aimed to compare the EGFR mutation-guided target therapy versus empirical chemotherapy for first-line treatment of advanced NSCLC in the...

Descripción completa

Detalles Bibliográficos
Autores principales: You, Joyce H. S., Cho, William C. S., Ming, Wai-kit, Li, Yu-chung, Kwan, Chung-kong, Au, Kwok-hung, Au, Joseph Siu-kie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920377/
https://www.ncbi.nlm.nih.gov/pubmed/33647045
http://dx.doi.org/10.1371/journal.pone.0247860

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920377/
https://www.ncbi.nlm.nih.gov/pubmed/33647045
http://dx.doi.org/10.1371/journal.pone.0247860

Ejemplares similares